MA49464A - TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES - Google Patents
TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSESInfo
- Publication number
- MA49464A MA49464A MA049464A MA49464A MA49464A MA 49464 A MA49464 A MA 49464A MA 049464 A MA049464 A MA 049464A MA 49464 A MA49464 A MA 49464A MA 49464 A MA49464 A MA 49464A
- Authority
- MA
- Morocco
- Prior art keywords
- associations
- corresponding processes
- targeted drug
- new compositions
- drug rescue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762501696P | 2017-05-04 | 2017-05-04 | |
TW106129169A TW201815387A (en) | 2016-08-26 | 2017-08-28 | Compositions and methods thereof |
US201862634162P | 2018-02-22 | 2018-02-22 | |
US201862636099P | 2018-02-27 | 2018-02-27 | |
US201862635554P | 2018-02-27 | 2018-02-27 | |
US201862636171P | 2018-02-28 | 2018-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49464A true MA49464A (en) | 2020-04-29 |
Family
ID=65431106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049464A MA49464A (en) | 2017-05-04 | 2018-05-03 | TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3618819A4 (en) |
JP (2) | JP7514078B2 (en) |
KR (2) | KR20200062078A (en) |
CN (1) | CN110831584B (en) |
AU (2) | AU2018261654A1 (en) |
BR (1) | BR112019022902A2 (en) |
CA (2) | CA3062452C (en) |
IL (1) | IL270326B2 (en) |
MA (1) | MA49464A (en) |
RU (1) | RU2760558C9 (en) |
TW (1) | TWI787260B (en) |
WO (1) | WO2018204713A1 (en) |
ZA (1) | ZA201908006B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021011203A (en) * | 2019-03-18 | 2022-09-07 | Avanir Pharmaceuticals Inc | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine. |
WO2020246143A1 (en) * | 2019-06-06 | 2020-12-10 | Jsr株式会社 | Radiation-sensitive resin composition, resist pattern formation method, and compound |
CN115667217A (en) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | Deuterated tryptamine derivatives and methods of use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4241065A (en) * | 1979-07-02 | 1980-12-23 | E. I. Du Pont De Nemours And Company | Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both |
US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US6207674B1 (en) | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
EP1986639A4 (en) | 2006-02-03 | 2010-04-28 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders |
EP2162135A4 (en) * | 2007-05-21 | 2012-02-22 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
US8017623B2 (en) * | 2008-07-03 | 2011-09-13 | Trinity Laboratories, Inc. | Dextromethorphan hydrochloride |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
JP6495191B2 (en) | 2013-03-07 | 2019-04-03 | マインドラブ・エルエルシー | Analgesic combinations and their use |
JP2016516202A (en) | 2013-03-15 | 2016-06-02 | キネメッド, インコーポレイテッド | Biomarker |
EP3503879A4 (en) * | 2016-08-26 | 2020-04-29 | EXCIVA GmbH | Compositions and methods thereof |
-
2018
- 2018-05-03 KR KR1020197035796A patent/KR20200062078A/en not_active Application Discontinuation
- 2018-05-03 MA MA049464A patent/MA49464A/en unknown
- 2018-05-03 CN CN201880037396.3A patent/CN110831584B/en active Active
- 2018-05-03 BR BR112019022902A patent/BR112019022902A2/en active Search and Examination
- 2018-05-03 WO PCT/US2018/030978 patent/WO2018204713A1/en active Application Filing
- 2018-05-03 KR KR1020217033764A patent/KR102444803B1/en active IP Right Grant
- 2018-05-03 AU AU2018261654A patent/AU2018261654A1/en not_active Abandoned
- 2018-05-03 RU RU2019137004A patent/RU2760558C9/en active
- 2018-05-03 EP EP18794381.6A patent/EP3618819A4/en active Pending
- 2018-05-03 JP JP2019560216A patent/JP7514078B2/en active Active
- 2018-05-03 CA CA3062452A patent/CA3062452C/en active Active
- 2018-05-03 CA CA3138116A patent/CA3138116A1/en active Pending
- 2018-05-04 TW TW107115320A patent/TWI787260B/en active
-
2019
- 2019-10-31 IL IL270326A patent/IL270326B2/en unknown
- 2019-12-02 ZA ZA2019/08006A patent/ZA201908006B/en unknown
-
2021
- 2021-08-13 AU AU2021215274A patent/AU2021215274B2/en active Active
-
2023
- 2023-07-21 JP JP2023119151A patent/JP2023143940A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3062452A1 (en) | 2018-11-08 |
AU2021215274B2 (en) | 2022-11-03 |
ZA201908006B (en) | 2021-04-28 |
IL270326B2 (en) | 2023-02-01 |
CA3062452C (en) | 2023-10-24 |
RU2760558C9 (en) | 2022-02-22 |
EP3618819A1 (en) | 2020-03-11 |
IL270326A (en) | 2018-05-03 |
KR20210130827A (en) | 2021-11-01 |
WO2018204713A1 (en) | 2018-11-08 |
BR112019022902A2 (en) | 2020-05-19 |
CN110831584B (en) | 2023-03-10 |
JP2023143940A (en) | 2023-10-06 |
TWI787260B (en) | 2022-12-21 |
RU2019137004A (en) | 2021-06-04 |
KR102444803B1 (en) | 2022-09-19 |
EP3618819A4 (en) | 2021-01-20 |
CA3138116A1 (en) | 2018-11-08 |
AU2018261654A1 (en) | 2019-11-14 |
KR20200062078A (en) | 2020-06-03 |
RU2760558C2 (en) | 2021-11-29 |
JP2020518617A (en) | 2020-06-25 |
JP7514078B2 (en) | 2024-07-10 |
IL270326B (en) | 2022-10-01 |
AU2021215274A1 (en) | 2021-09-02 |
CN110831584A (en) | 2020-02-21 |
RU2019137004A3 (en) | 2021-06-04 |
TW201842902A (en) | 2018-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49858A (en) | COMPOUNDS, COMPOSITIONS AND PROCESSES | |
MA50063A (en) | COMPOUNDS, COMPOSITIONS AND PROCESSES | |
BR112018003110A2 (en) | therapeutic nanoparticles comprising a therapeutic agent and methods of manufacturing and using them | |
DK3258939T3 (en) | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF | |
DK3705488T3 (en) | NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF | |
DK3297605T3 (en) | TOPIC, PHARMACEUTICAL COMPOSITIONS | |
DK3580561T3 (en) | HLA-BASED METHODS, COMPOSITIONS AND USES THEREOF | |
BR112016018521A2 (en) | composition and kit. | |
CL2018000565A1 (en) | Compounds derived from pyridinone dicarboxamide, bromodomain inhibitors; pharmaceutical composition; pharmaceutical combination; Useful in the treatment of autoimmune, inflammatory, viral and cancer diseases, among others. | |
DK3223796T3 (en) | PHARMACEUTICAL COMPOSITIONS, MANUFACTURING AND USES | |
MA49633A (en) | AGENTS, USES AND TREATMENT METHODS | |
MA47516A (en) | PHARMACEUTICAL COMPOSITION | |
MA49464A (en) | TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES | |
DK3383397T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRIN, TENOFOVIRDISOPROXILFUMARAT AND LAMIVUDIN | |
CL2020000973A1 (en) | Compositions and procedures for the treatment of diffuse large b-cell lymphoma. | |
DK4023651T3 (en) | OPTICALLY ACTIVE PYRANOCHROMENYLPHENOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
FR3024733B1 (en) | THICKENING AGENT FOR AQUEOUS SYSTEMS, FORMULATIONS CONTAINING THE SAME AND USES THEREOF. | |
DK3424500T3 (en) | PHARMACEUTICAL COMPOSITION INCLUDING FAMITINIB | |
DK3153163T3 (en) | PHARMACEUTICAL COMPOUND CONTAINING 13 GLYCERIDES, FORMULATION AND USE THEREOF | |
MA56458A (en) | MACITENTAN TABLET COMPOSITIONS, METHODS AND USES THEREOF | |
IT201700119847A1 (en) | FAN STRUCTURE WITH AIR TREATMENT DEVICE. | |
TH1601003241A (en) | Use of benzimidazole-proline derivatives | |
RU2014107124A (en) | EXPLOSIVE COMPOSITION BASED ON HEXOGENE | |
IT201700028709A1 (en) | ACIDS-5-CARBOSSAMIDE-2-THIOBARBITURIS AND THEIR USE AS MEDICATIONS | |
FR3046907B1 (en) | ANTIFUNGAL AGENT, PROCESS AND COMPOSITION |